TIDMSBI
RNS Number : 8349B
SourceBio International PLC
14 June 2021
14 June 2021
SourceBio International plc
('SourceBio')
RESULT OF ANNUAL GENERAL MEETING
SourceBio confirms that all resolutions put to the 2021 Annual
General Meeting held on the 14 June were
duly passed by the required majority.
Voting on the resolutions was as follows:
Resolution Description For Against Withheld
To receive and approve the Company's
Annual Report and Accounts for
the financial year ended 31 December
2020 together with the Directors'
Report (including the Strategic
1 Report) and the Auditor's Report. 58,529,422 802 400
------------------------------------------- ----------- -------- ---------
To receive and approve the Directors'
Remuneration Report for the financial
year ended 31 December 2020, excluding
the proposed remuneration policy,
executive share options plan and
2 Save As You Earn ("SAYE") scheme. 58,523,385 7,239 Nil
------------------------------------------- ----------- -------- ---------
To approve the proposed remuneration
policy expected to be applied
3 in 2021. 57,772,392 8,232 750,000
------------------------------------------- ----------- -------- ---------
To approve the establishment and
implementation of a proposed executive
4 share options plan. 57,767,232 8,392 755,000
------------------------------------------- ----------- -------- ---------
To approve the establishment and
implementation of a proposed SAYE
5 scheme. 58,527,668 1,556 1,400
------------------------------------------- ----------- -------- ---------
To re-elect Jay LeCoque (Executive
Chairman) as a Director of the
6 Company. 58,529,756 868 Nil
------------------------------------------- ----------- -------- ---------
To re-elect Tony Ratcliffe (Chief
Financial Officer) as a Director
7 of the Company. 58,530,624 Nil Nil
------------------------------------------- ----------- -------- ---------
To re-elect Sir Ian Carruthers
(Senior Independent Non-Executive
Director) as a Director of the
8 Company. 58,526,545 3,748 331
------------------------------------------- ----------- -------- ---------
To re-elect Simon Constantine
(Independent Non-Executive Director)
9 as a Director of the Company. 58,529,091 1,533 Nil
------------------------------------------- ----------- -------- ---------
To re-elect Marco Fumagalli (Non-Executive
Director) as a Director of the
10 Company. 58,529,956 668 Nil
------------------------------------------- ----------- -------- ---------
To re-elect Christopher Mills
(Non-Executive Director) as a
11 Director of the Company. 58,528,891 1,733 Nil
------------------------------------------- ----------- -------- ---------
To re-appoint RSM UK Audit LLP
as auditor of the Company and
to authorise the Directors to
12 fix their remuneration. 58,529,024 1,600 Nil
------------------------------------------- ----------- -------- ---------
To authorise the Directors generally
to allot ordinary shares up to
13 the specified limit. 58,524,551 5,673 400
------------------------------------------- ----------- -------- ---------
To empower the Directors to issue
shares free from statutory pre-emption
14 * rights up to the specified limit. 58,518,215 12,409 Nil
------------------------------------------- ----------- -------- ---------
To authorise amendment to the
15 * Company's Articles of Association. 58,524,345 1,279 5,000
------------------------------------------- ----------- -------- ---------
* Special Resolution
A trading update was released at 7.00am this morning.
Notes:
-- Any proxy appointments which gave direction to the Executive
Chairman have been included in the "for" column;
-- The total number of shares in issue is 74,183,038
Contacts :
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Advisor and Broker) Tel: 020 3100 2000
Bidhi Bhoma
Richard Lindley
Euan Brown
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502
558 258
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products with clients in
the healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four core businesses
areas:
-- Infectious Disease Testing - a range of COVID-19 testing
services for commercial enterprises, private healthcare groups, NHS
and the DHSC. Utilising multiple technologies, SourceBio offers
screening, gold standard RT-PCR and whole genome sequencing
COVID-19 testing solutions and operates under ISO 15189
accreditation required by the DHSC. SourceBio also provides
employee testing solutions to industry, direct to consumer home
test kits (including 'Fit to Fly', 'Test to Release' and '2 & 8
Day International Travel' approved tests) whilst also being the
lead operator on mobile testing unit services to support outbreak
testing for the DHSC, event and venue testing.
-- Healthcare Diagnostics - histopathology cancer screening and
clinical diagnostic services for the NHS and private healthcare
across the UK and Ireland.
-- Genomics - DNA sequencing services for pharmaceutical and
biotechnology companies, academia, contract research organisations
(CROs) and other research groups in the UK, Europe and North
America.
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here:
www.sourcebioscience.com
SourceBio International plc (SBI) is listed on the AIM market of
the London Stock Exchange.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUSVURAAUNAAR
(END) Dow Jones Newswires
June 14, 2021 09:08 ET (13:08 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024
